Naslov
Antinociceptive activity of botulinum toxin type A

Autori
Laković, Zdravko ; Bach-Rojecky, Lidija ; Relja, Maja

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the 16th International Congress on Parkinson's Disease and Related Disorders ; u: Parkinsonism & related disorders 11 (2005) (S2) ; Poster symposia ; PS004 Botulinum toxin 105-106 / - , 2005, 105-105

Skup
International Congress on Parkinson's Disease and Related Disorders (16 ; 2005)

Mjesto i datum
,

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Botulinum toxin type A; pain

Sažetak
Objective: Over the last 20 years botulinum toxin type A (BTX-A) has beeen used for treating a varity of disorders characgterized by increased muscle contraction and recently few clinical observations on several patients indicated that it might be useful in neuropathic pain. Here we owerview the efficacy of BTX-a in different models of pain in rat, from published studies and some new studies from our laboratory. Methods: All experiments were performed in rats. After dose-response and time-course experiments performed with BTX-A using formalin to provoke acute pain associated with inflammation the effectiveness of BTX-A on pain was tested. Results: 1. Pre-treatment with BTX-A 5 U/kg reduced enhances sensitvity to stimuli provoked with peripheral carrageenan or capsaicin injection. This reduction was significant then BTX-A was aplied 6 days before the induction of pain and wa ineffective when applied 24 h before the challenge. 2.A peripheral application of botulinum toxin type A (7 U/kg) reduced hypersensitivity in rats with the partial sciatic nerve transection. 3. BTX-A was effective in pain induced injection of low pH Saline Conclusions: The results obtained in our laboratory clearly demonstrate antinociceptive activity of small doses of BTX-A in experimental animals. Since single applicaton of BTX-A in rat produces antinociceptive effect lasting 12-15 days or more the potential significance for pain pharmacology is more than clear. However, (a) five days delay in the onset of antinociceptive activity of peripherally applied BTX-A, (b) its effectivness in different models of experimental pain, (c) its inefectiveness in reducing carrageenan iduced paw-edema indicate that the nociceptive effect of BTX-A might be more complex than suggested inhibition of transmitter release in the periphery.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

Napomena
Peter Franz Riederer, Susanne W. Burns, Manfred Gerlach (ur.) ; DOI: 10.1016/S1353-8020(05)80088-4

POVEZANOST RADA